XTX Topco Ltd Makes New Investment in Emergent Biosolutions Inc. (NYSE:EBS)

Key Points

• XTX Topco Ltd acquired a new stake in Emergent Biosolutions Inc. by purchasing 85,812 shares valued at approximately $417,000, representing about 0.16% ownership in the company.
• Emergent Biosolutions recently reported a quarterly EPS of $0.16, exceeding analysts' expectations, although its revenue of $140.90 million fell short of the consensus estimate.
• Institutional investors now hold 78.40% of Emergent Biosolutions' stock, highlighting significant hedge fund interest in the biopharmaceutical company.

XTX Topco Ltd purchased a new stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 85,812 shares of the biopharmaceutical company's stock, valued at approximately $417,000. XTX Topco Ltd owned approximately 0.16% of Emergent Biosolutions at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in EBS. Covestor Ltd boosted its position in Emergent Biosolutions by 5,458.5% during the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 2,893 shares during the period. SBI Securities Co. Ltd. increased its stake in shares of Emergent Biosolutions by 95.1% during the first quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 6,313 shares in the last quarter. Corton Capital Inc. bought a new position in shares of Emergent Biosolutions during the first quarter valued at approximately $70,000. Bank of New York Mellon Corp increased its position in shares of Emergent Biosolutions by 40.4% during the first quarter. Bank of New York Mellon Corp now owns 17,003 shares of the biopharmaceutical company's stock valued at $83,000 after acquiring an additional 4,894 shares in the last quarter. Finally, EP Wealth Advisors LLC bought a new stake in shares of Emergent Biosolutions during the fourth quarter valued at approximately $110,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent Biosolutions Stock Performance

Shares of Emergent Biosolutions stock traded down $0.02 on Wednesday, hitting $8.90. 401,060 shares of the company's stock were exchanged, compared to its average volume of 1,254,265. The company has a 50-day simple moving average of $6.81 and a 200-day simple moving average of $6.61. The stock has a market capitalization of $474.55 million, a PE ratio of 3.64 and a beta of 1.97. Emergent Biosolutions Inc. has a 1 year low of $4.02 and a 1 year high of $13.28. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.00 and a current ratio of 5.66.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.42. The business had revenue of $140.90 million for the quarter, compared to analysts' expectations of $148.55 million. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. As a group, equities analysts anticipate that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Insider Buying and Selling at Emergent Biosolutions

In related news, Director Keith Katkin sold 7,844 shares of Emergent Biosolutions stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $6.30, for a total transaction of $49,417.20. Following the transaction, the director owned 86,431 shares in the company, valued at approximately $544,515.30. The trade was a 8.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a research report on Saturday.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.